L
ltnriley
Iron
- Joined
- Apr 30, 2026
- Posts
- 27
- Reputation
- 6
For the record, I made this guide and was preparing to format and upload it to tiktok. Most of this is speculative, and if im wrong please tell me.
KY19382 Master Guide Pt. 1
Overview
A lot of people recently have been talking about KY19382 for hair growth, linear growth, and even effects on opening closed growth plates, and even creating new epiphyseal chondrocytes, but what actually is KY19382? KY19382 is an experimental small-molecule chemical that blocks CXXC5-DVL and GSK3β. CXXC5 (CXXC finger protein 5) is a regulatory protein that contains a CXXC zinc-finger domain. It can bind to DVL proteins and influence Wnt signaling. Dishevelled (DVL) is a central signaling protein in the Wnt pathway. When Wnt signaling is activated, Wnt binds to Frizzled/LRP receptors, DVL becomes activated, β-catenin is stabilized, β-catenin enters the nucleus, and growth-related genes are turned on. When CXXC5 binds DVL, DVL activity, β-catenin signaling, and canonical Wnt pathway activation all decrease. Hence, blocking CXXC5-DVL interaction can cause Wnt signaling. Wnt signaling is crucial for cell movement, cell shape, and how unshaped cells turn into specialized tissue during body growth and adult repair. So how does this relate to epiphyseal plates, hair growth, and linear height growth? Researchers have looked at CXXC5–DVL inhibition because increasing Wnt signaling can affect: hair follicle regeneration, bone formation, stem cell activity, and tissue repair. Theoretically, this could create new growth plate cartilage and chondrocytes as Wnt signaling can influence mesenchymal stem cell behavior, chondrocyte formation, and cartilage development pathways.
Synergy with Erdafitinib
KY19382’s effects can synergize very well with something like Erdafitinib. Erdafitinib is a potent fgfr1-4 Inhibitor, the primary pathway utilized for height is fgfr3. Fgfr3 is the brake on your body’s bone growth. When it is inhibited with something like Erdafitinib, linear growth speeds increase drastically. Although potentially more efficacious compounds such as Tyra-300 may exist, Erdafitinib is the most budget friendly and widely available. Erdafitinib can produce side effects beyond what is immediately visible. Retinal issues are associated with inhibition of FGFR signaling. FGFRs are expressed in many different tissues, not just the retina, raising the question of how FGFR inhibition affects the body more broadly. FGFR1 signaling helps regulate chondrocyte proliferation and differentiation, meaning that inhibiting this pathway could potentially decrease chondrocyte proliferation, which is an important component of longitudinal bone growth. This raises the question: could activating regenerative pathways such as Wnt potentially influence some downstream consequences of FGFR inhibition? To answer this question, we need to examine how separate growth-regulatory pathways interact when they produce opposing signals. In most situations where two or more growth-regulatory pathways exert counteracting influences, the resulting effects depend on factors such as relative pathway strength, timing, and the developmental stage of the affected cells. Although inhibition of FGFR3 can promote longitudinal bone growth by reducing one of the major inhibitory signals acting on growth-plate chondrocytes, this does not capture the full biological consequences of broad FGFR1–4 inhibition. Erdafitinib simultaneously suppresses several FGFR pathways with distinct roles in cartilage, bone, and other tissues, meaning that inhibition of receptors such as FGFR1 could potentially introduce counteracting or undesirable effects that limit the theoretical benefits of FGFR3 inhibition. FGFR1 signaling contributes to growth plate regulation by influencing chondrocyte proliferation, differentiation, and maturation. Because growth plate expansion relies on a balance between maintaining proliferative chondrocytes and allowing controlled maturation, disrupting FGFR1 activity could potentially alter this balance. Reduced FGFR1 signaling could theoretically shift chondrocytes toward a less proliferative state, decreasing the pool of cells available for continued growth plate activity. The Wnt/β-catenin pathway represents another major regulator of cell fate, influencing progenitor maintenance, proliferation, and differentiation. Activation of Wnt signaling could theoretically provide an opposing signal to pathways that reduce proliferative activity. However, FGFR and Wnt signaling do not operate independently. Both pathways converge on cellular processes such as proliferation and differentiation, meaning that activation of one pathway may alter how cells respond to the other. The outcome of their interaction would depend on factors including signal intensity, duration, and the specific developmental state of the cell. Therefore, an important question is whether enhanced Wnt/β-catenin signaling could partially compensate for reduced FGFR activity by preserving chondrocyte proliferation or altering differentiation patterns within growth plate tissue. While this concept remains hypothetical, it presents an intriguing area for further investigation. Understanding the interaction between FGFR inhibition and Wnt/β-catenin activation could reveal whether these pathways can modulate each other’s effects within growth plate biology. If compensatory mechanisms exist, targeted pathway interactions may provide insight into regulating chondrocyte activity and longitudinal bone growth. In summary, although this concept remains hypothetical, it presents an intriguing possibility that modulation of regenerative pathways such as Wnt/β-catenin could influence some downstream effects of FGFR inhibition. Further research into the interaction between these pathways may clarify whether their relationship influences chondrocyte activity, growth plate function, and longitudinal bone growth. Additionally, the potential protective effects of KY19382 against FGFR-inhibition-associated retinal changes may extend to other FGFR-expressing tissues. For example, FGFR signaling plays an important role in dermal and epidermal tissue repair. Inhibition of this pathway can impair processes involved in wound healing, including keratinocyte proliferation and migration, fibroblast signaling, angiogenesis, and tissue-repair signaling, potentially resulting in slower re-epithelialization and delayed wound closure. Therefore, if KY19382 is capable of mitigating some consequences of FGFR inhibition, its effects may not be limited to retinal tissue and could potentially extend to other FGFR-dependent tissues. This is extremely beneficial to mitigating side effects as it could apply to other tissues and cells with large amounts of FGFR expression such as the kidneys, intestines, vascular/mesenchymal stem cells, the nervous system, chondrocytes, the liver, skin and keratinocytes, lungs, developing bone, and epithelial tissue.
TLDR
KY19382 is an experimental small molecule that activates Wnt/β-catenin signaling by inhibiting GSK3β and disrupting the CXXC5–DVL interaction, pathways involved in tissue regeneration, hair growth, stem-cell activity, bone formation, and growth-plate biology. Animal research suggests that KY19382 can increase growth-plate chondrocyte proliferation and differentiation, delay growth-plate senescence, and enhance longitudinal bone growth, although claims that it can reopen fully fused growth plates remain speculative. A proposed synergy with erdafitinib comes from the fact that erdafitinib inhibits FGFR1–4, including FGFR3, which normally acts as an important negative regulator of growth-plate activity, while also inhibiting other FGFR pathways that have useful roles in chondrocytes, bone, skin, the retina, kidneys, intestines, nervous system, and other tissues. Because Wnt and FGFR signaling both influence proliferation, differentiation, and tissue repair, enhanced Wnt signaling could theoretically modify or partially compensate for some effects of broad FGFR inhibition, including changes in growth-plate cell behavior and tissue repair. However, whether KY19382 can actually improve the growth effects of erdafitinib or protect against FGFR-inhibition-associated side effects is not certain, but the possibilities seem highly promising.
My Recommendation
I believe KY19382 shows promising possibilities for widening open epiphyseal plates or even opening epiphyseal plates that are fully closed. I am also very confident that KY19382 synergizes very well with Erdafitinib. With this in mind, I recommend anyone using Erdafitinib to use 0.5-1mg of Injectable KY19382. Additionally, KY19382 can work very well on its own for hair growth and longitudinal bone growth. In summary, I believe KY19382 synergizes very well with Erdafitinib and can help reduce side effects while also boosting the efficaciousness of the compound.
KY19382 Master Guide Pt. 1
Overview
A lot of people recently have been talking about KY19382 for hair growth, linear growth, and even effects on opening closed growth plates, and even creating new epiphyseal chondrocytes, but what actually is KY19382? KY19382 is an experimental small-molecule chemical that blocks CXXC5-DVL and GSK3β. CXXC5 (CXXC finger protein 5) is a regulatory protein that contains a CXXC zinc-finger domain. It can bind to DVL proteins and influence Wnt signaling. Dishevelled (DVL) is a central signaling protein in the Wnt pathway. When Wnt signaling is activated, Wnt binds to Frizzled/LRP receptors, DVL becomes activated, β-catenin is stabilized, β-catenin enters the nucleus, and growth-related genes are turned on. When CXXC5 binds DVL, DVL activity, β-catenin signaling, and canonical Wnt pathway activation all decrease. Hence, blocking CXXC5-DVL interaction can cause Wnt signaling. Wnt signaling is crucial for cell movement, cell shape, and how unshaped cells turn into specialized tissue during body growth and adult repair. So how does this relate to epiphyseal plates, hair growth, and linear height growth? Researchers have looked at CXXC5–DVL inhibition because increasing Wnt signaling can affect: hair follicle regeneration, bone formation, stem cell activity, and tissue repair. Theoretically, this could create new growth plate cartilage and chondrocytes as Wnt signaling can influence mesenchymal stem cell behavior, chondrocyte formation, and cartilage development pathways.
Synergy with Erdafitinib
KY19382’s effects can synergize very well with something like Erdafitinib. Erdafitinib is a potent fgfr1-4 Inhibitor, the primary pathway utilized for height is fgfr3. Fgfr3 is the brake on your body’s bone growth. When it is inhibited with something like Erdafitinib, linear growth speeds increase drastically. Although potentially more efficacious compounds such as Tyra-300 may exist, Erdafitinib is the most budget friendly and widely available. Erdafitinib can produce side effects beyond what is immediately visible. Retinal issues are associated with inhibition of FGFR signaling. FGFRs are expressed in many different tissues, not just the retina, raising the question of how FGFR inhibition affects the body more broadly. FGFR1 signaling helps regulate chondrocyte proliferation and differentiation, meaning that inhibiting this pathway could potentially decrease chondrocyte proliferation, which is an important component of longitudinal bone growth. This raises the question: could activating regenerative pathways such as Wnt potentially influence some downstream consequences of FGFR inhibition? To answer this question, we need to examine how separate growth-regulatory pathways interact when they produce opposing signals. In most situations where two or more growth-regulatory pathways exert counteracting influences, the resulting effects depend on factors such as relative pathway strength, timing, and the developmental stage of the affected cells. Although inhibition of FGFR3 can promote longitudinal bone growth by reducing one of the major inhibitory signals acting on growth-plate chondrocytes, this does not capture the full biological consequences of broad FGFR1–4 inhibition. Erdafitinib simultaneously suppresses several FGFR pathways with distinct roles in cartilage, bone, and other tissues, meaning that inhibition of receptors such as FGFR1 could potentially introduce counteracting or undesirable effects that limit the theoretical benefits of FGFR3 inhibition. FGFR1 signaling contributes to growth plate regulation by influencing chondrocyte proliferation, differentiation, and maturation. Because growth plate expansion relies on a balance between maintaining proliferative chondrocytes and allowing controlled maturation, disrupting FGFR1 activity could potentially alter this balance. Reduced FGFR1 signaling could theoretically shift chondrocytes toward a less proliferative state, decreasing the pool of cells available for continued growth plate activity. The Wnt/β-catenin pathway represents another major regulator of cell fate, influencing progenitor maintenance, proliferation, and differentiation. Activation of Wnt signaling could theoretically provide an opposing signal to pathways that reduce proliferative activity. However, FGFR and Wnt signaling do not operate independently. Both pathways converge on cellular processes such as proliferation and differentiation, meaning that activation of one pathway may alter how cells respond to the other. The outcome of their interaction would depend on factors including signal intensity, duration, and the specific developmental state of the cell. Therefore, an important question is whether enhanced Wnt/β-catenin signaling could partially compensate for reduced FGFR activity by preserving chondrocyte proliferation or altering differentiation patterns within growth plate tissue. While this concept remains hypothetical, it presents an intriguing area for further investigation. Understanding the interaction between FGFR inhibition and Wnt/β-catenin activation could reveal whether these pathways can modulate each other’s effects within growth plate biology. If compensatory mechanisms exist, targeted pathway interactions may provide insight into regulating chondrocyte activity and longitudinal bone growth. In summary, although this concept remains hypothetical, it presents an intriguing possibility that modulation of regenerative pathways such as Wnt/β-catenin could influence some downstream effects of FGFR inhibition. Further research into the interaction between these pathways may clarify whether their relationship influences chondrocyte activity, growth plate function, and longitudinal bone growth. Additionally, the potential protective effects of KY19382 against FGFR-inhibition-associated retinal changes may extend to other FGFR-expressing tissues. For example, FGFR signaling plays an important role in dermal and epidermal tissue repair. Inhibition of this pathway can impair processes involved in wound healing, including keratinocyte proliferation and migration, fibroblast signaling, angiogenesis, and tissue-repair signaling, potentially resulting in slower re-epithelialization and delayed wound closure. Therefore, if KY19382 is capable of mitigating some consequences of FGFR inhibition, its effects may not be limited to retinal tissue and could potentially extend to other FGFR-dependent tissues. This is extremely beneficial to mitigating side effects as it could apply to other tissues and cells with large amounts of FGFR expression such as the kidneys, intestines, vascular/mesenchymal stem cells, the nervous system, chondrocytes, the liver, skin and keratinocytes, lungs, developing bone, and epithelial tissue.
TLDR
KY19382 is an experimental small molecule that activates Wnt/β-catenin signaling by inhibiting GSK3β and disrupting the CXXC5–DVL interaction, pathways involved in tissue regeneration, hair growth, stem-cell activity, bone formation, and growth-plate biology. Animal research suggests that KY19382 can increase growth-plate chondrocyte proliferation and differentiation, delay growth-plate senescence, and enhance longitudinal bone growth, although claims that it can reopen fully fused growth plates remain speculative. A proposed synergy with erdafitinib comes from the fact that erdafitinib inhibits FGFR1–4, including FGFR3, which normally acts as an important negative regulator of growth-plate activity, while also inhibiting other FGFR pathways that have useful roles in chondrocytes, bone, skin, the retina, kidneys, intestines, nervous system, and other tissues. Because Wnt and FGFR signaling both influence proliferation, differentiation, and tissue repair, enhanced Wnt signaling could theoretically modify or partially compensate for some effects of broad FGFR inhibition, including changes in growth-plate cell behavior and tissue repair. However, whether KY19382 can actually improve the growth effects of erdafitinib or protect against FGFR-inhibition-associated side effects is not certain, but the possibilities seem highly promising.
My Recommendation
I believe KY19382 shows promising possibilities for widening open epiphyseal plates or even opening epiphyseal plates that are fully closed. I am also very confident that KY19382 synergizes very well with Erdafitinib. With this in mind, I recommend anyone using Erdafitinib to use 0.5-1mg of Injectable KY19382. Additionally, KY19382 can work very well on its own for hair growth and longitudinal bone growth. In summary, I believe KY19382 synergizes very well with Erdafitinib and can help reduce side effects while also boosting the efficaciousness of the compound.
